What is Zevra Therapeutics, Inc.'s business segments — SG&A?

Zevra Therapeutics, Inc. (ZVRA) reported business segments — SG&A of $14.35M in Q1 2026.

How has Zevra Therapeutics, Inc.'s business segments — SG&A changed year-over-year?

Zevra Therapeutics, Inc.'s business segments — SG&A increased by 19.8% year-over-year, from $11.98M to $14.35M.

What does business segments — SG&A mean?

Includes the overhead, marketing, and administrative expenses required to support the segment's operations and commercialization efforts. This metric reflects the operational efficiency and the cost structure required to maintain the business segment's market presence.

Zevra Therapeutics, Inc. ZVRA Business Segments — SG&A

Similar metrics at other companies

TVTXReportable Segment — SG&A

$80.25M+32.8%

SATLReportable Segment — SG&A

$6.55M+0.9%

INDVReportable Segment — SG&A

$124M-6.8%

AGIOReportable Segment — SG&A

$48.3M+16.3%

LCIDReportable Segment — SG&A

$304.18M+43.4%

VIRReportable Segment — SG&A

$23.34M-2.5%

Other financials

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation

See full

Market cap$773.23M+56.4%

Enterprise value$678.78M+30.8%

P/E6.2×—

P/S6.3×-5.9×

Profitability

See full

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s business segments — sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s business segments — SG&A?: Zevra Therapeutics, Inc. (ZVRA) reported business segments — SG&A of $14.35M in Q1 2026.
How has Zevra Therapeutics, Inc.'s business segments — SG&A changed year-over-year?: Zevra Therapeutics, Inc.'s business segments — SG&A increased by 19.8% year-over-year, from $11.98M to $14.35M.
What does business segments — SG&A mean?: Includes the overhead, marketing, and administrative expenses required to support the segment's operations and commercialization efforts. This metric reflects the operational efficiency and the cost structure required to maintain the business segment's market presence.